In refiling $16.5B Catalent buyout pitch, Novo gives FTC more time for review
In refiling $16.5B Catalent buyout pitch, Novo gives FTC more time for review fkansteiner Fri, 04/05/2024 - 15:15
In refiling $16.5B Catalent buyout pitch, Novo gives FTC more time for review fkansteiner Fri, 04/05/2024 - 15:15
As Humira biosim sales languish, Boehringer Ingelheim plots layoffs in pivot to hybrid marketing model fkansteiner Fri, 04/05/2024 - 11:07
Bristol Myers’ Abecma wins FDA nod in earlier multiple myeloma with updated boxed warning on secondary cancer aliu Fri, 04/05/2024 - 11:06
Inclusive Innovation: Key to the Future of Healthcare jpiatt Fri, 04/05/2024 - 10:37
High-flying Vertex hikes CEO Reshma Kewalramani's pay by 30% to $20.6M kdunleavy Fri, 04/05/2024 - 10:19
House committee to press FDA Commissioner Robert Califf on shortage oversight, other issues zbecker Fri, 04/05/2024 - 09:54
AstraZeneca’s Imfinzi tackles another type of lung cancer with latest trial win esagonowsky Fri, 04/05/2024 - 09:20
Novartis finally ready for Pluvicto filing in earlier prostate cancer as patient survival data clear up aliu Fri, 04/05/2024 - 00:01